Abstract
Background: We conducted a prospective clinical trial of combination neoadjuvant chemotherapy, transoral robotic surgery (TORS), and customized adjuvant therapy in patients with locally advanced laryngo-hypopharyngeal cancer. Methods: Between September 2008 and August 2016, 35 patients were enrolled in this clinical trial. Results: Twenty patients had hypopharyngeal cancer and 15 had laryngeal cancer. Twenty-nine patients (82.9%) had T3 disease and six patients (17.1%) had T4 disease, while 12 patients (34.3%) had stage III disease and 23 patients (65.7%) had stage IV disease. The 3-year disease-specific survival rate was 82.4% and the 3-year disease-free survival rate was 69.48%. Decannulation was successful in 31 of 34 patients at an average of 18 days postoperatively. Among all patients, 83% exhibited a favorable subjective swallowing status, while five patients (14.4%) became dependent on feeding tubes. Conclusions: Neoadjuvant chemotherapy combined with TORS and customized adjuvant therapy, based on detailed pathological information, afforded favorable oncological outcomes and preserved organ functionalities in T3–T4 laryngo-hypopharyngeal cancer.
| Original language | English |
|---|---|
| Pages (from-to) | 864-871 |
| Number of pages | 8 |
| Journal | Annals of Surgical Oncology |
| Volume | 25 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - 2018 Apr 1 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Surgery
- Oncology
Cite this
}
A Clinical Trial of Combination Neoadjuvant Chemotherapy and Transoral Robotic Surgery in Patients with T3 and T4 Laryngo-Hypopharyngeal Cancer. / Park, Young Min; Keum, Ki Chang; Kim, Hye Ryun; Cho, Byoung Chul; Kim, Da Hee; Cho, Nam Hoon; Kim, Se Heon.
In: Annals of Surgical Oncology, Vol. 25, No. 4, 01.04.2018, p. 864-871.Research output: Contribution to journal › Article
TY - JOUR
T1 - A Clinical Trial of Combination Neoadjuvant Chemotherapy and Transoral Robotic Surgery in Patients with T3 and T4 Laryngo-Hypopharyngeal Cancer
AU - Park, Young Min
AU - Keum, Ki Chang
AU - Kim, Hye Ryun
AU - Cho, Byoung Chul
AU - Kim, Da Hee
AU - Cho, Nam Hoon
AU - Kim, Se Heon
PY - 2018/4/1
Y1 - 2018/4/1
N2 - Background: We conducted a prospective clinical trial of combination neoadjuvant chemotherapy, transoral robotic surgery (TORS), and customized adjuvant therapy in patients with locally advanced laryngo-hypopharyngeal cancer. Methods: Between September 2008 and August 2016, 35 patients were enrolled in this clinical trial. Results: Twenty patients had hypopharyngeal cancer and 15 had laryngeal cancer. Twenty-nine patients (82.9%) had T3 disease and six patients (17.1%) had T4 disease, while 12 patients (34.3%) had stage III disease and 23 patients (65.7%) had stage IV disease. The 3-year disease-specific survival rate was 82.4% and the 3-year disease-free survival rate was 69.48%. Decannulation was successful in 31 of 34 patients at an average of 18 days postoperatively. Among all patients, 83% exhibited a favorable subjective swallowing status, while five patients (14.4%) became dependent on feeding tubes. Conclusions: Neoadjuvant chemotherapy combined with TORS and customized adjuvant therapy, based on detailed pathological information, afforded favorable oncological outcomes and preserved organ functionalities in T3–T4 laryngo-hypopharyngeal cancer.
AB - Background: We conducted a prospective clinical trial of combination neoadjuvant chemotherapy, transoral robotic surgery (TORS), and customized adjuvant therapy in patients with locally advanced laryngo-hypopharyngeal cancer. Methods: Between September 2008 and August 2016, 35 patients were enrolled in this clinical trial. Results: Twenty patients had hypopharyngeal cancer and 15 had laryngeal cancer. Twenty-nine patients (82.9%) had T3 disease and six patients (17.1%) had T4 disease, while 12 patients (34.3%) had stage III disease and 23 patients (65.7%) had stage IV disease. The 3-year disease-specific survival rate was 82.4% and the 3-year disease-free survival rate was 69.48%. Decannulation was successful in 31 of 34 patients at an average of 18 days postoperatively. Among all patients, 83% exhibited a favorable subjective swallowing status, while five patients (14.4%) became dependent on feeding tubes. Conclusions: Neoadjuvant chemotherapy combined with TORS and customized adjuvant therapy, based on detailed pathological information, afforded favorable oncological outcomes and preserved organ functionalities in T3–T4 laryngo-hypopharyngeal cancer.
UR - http://www.scopus.com/inward/record.url?scp=85032703377&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85032703377&partnerID=8YFLogxK
U2 - 10.1245/s10434-017-6208-5
DO - 10.1245/s10434-017-6208-5
M3 - Article
C2 - 29086129
AN - SCOPUS:85032703377
VL - 25
SP - 864
EP - 871
JO - Annals of Surgical Oncology
JF - Annals of Surgical Oncology
SN - 1068-9265
IS - 4
ER -